The Role of Biomarkers in Immunotherapy Selection for mUC

“How do we personalize and improve patient selection for frontline treatment now that patients are living, on average, more than 2 years with this aggressive cancer?” said David H. Aggen, MD, PhD

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Disease-free survival and overall survival were lower with extended lymphadenectomy compared with standard lymphadenectomy.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

The decision is backed by robust efficacy data from the phase 3 ENVISION trial, evaluating UGN-102 in patients with non-muscle invasive bladder cancer.

TAR-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.